Wells Fargo将Merck升级为“超重”, 引用了强大的毒品管道和Keyturda的成功。 Wells Fargo upgrades Merck to "Overweight" citing strong drug pipeline and Keytruda's success.

Wells Fargo将Merck & Co.提升为“超重”, 将其价格目标提升至125美元, Wells Fargo upgraded Merck & Co. to "Overweight" and raised its price target to $125, citing strong progress in its drug pipeline, particularly in oncology and infectious diseases, along with continued success of its blockbuster drug Keytruda. 该公司强调Merck公司纪律严明的资本使用和强有力的研发是关键优势,表明对该公司增长前景和股东在不断变化的保健动态中回报的信心。 The firm highlighted Merck’s disciplined capital use and robust R&D as key strengths, signaling confidence in the company’s growth prospects and shareholder returns amid shifting healthcare dynamics.